An NCI-designated Comprehensive Cancer Center

Matthew Genyeh Mei, M.D.

Hematologist - Oncologist
Clinical Expertise
Assistant Clinical Professor, Department of Department of Hematology & Hematopoietic Cell Transplantation
Other Languages Spoken
  • Mandarin
  • Spanish

Clinical Teams

I became a physician because I wanted to balance my love for science with a desire to help people.
Passionate and energetic, Matthew G. Mei, M.D., specializes in treating lymphoma and advancing the field of stem cell transplants. “The thing I love most about this field is,” he says, “we routinely — and not just once in a while — we routinely take patients with some of the worst malignancies out there ... and we cure them!”
The Harvard-educated Dr. Mei earned his medical degree at Case Western Reserve University in Cleveland. He completed his residency at University of California San Francisco, joined City of Hope as a hematology/oncology fellow in 2011, and became an assistant clinical professor in 2014.
Dr. Mei loves City of Hope's dual mission of leading-edge research and compassionate care. He calls City of Hope a “top-flight research institution which is helping to advance the state of the art in cancer care yet has not lost sight of the patient as a whole person.”


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S. Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones. Biol Blood Marrow Transplant. 2019 Jan 29.
  • Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, Budde E, Nademanee A, Forman SJ, Nakamura R. Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus and tacrolimus based GVHD prophylaxis. Biol Blood Marrow Transplant. 2019 Feb;25(2):287-292.
  • Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating Agents in combination with Venetoclax for Acute Myeloid Leukemia: Update on Clinical trial data and Practical Considerations for use. Am J Hematol. 2018 Nov 30.
  • Padeganeh A, Song J, Aoun P, Mei M, Ali H, Weisenburger DD, Murata-Collins JL. Clinical Relevance of Normal Diploid Workflow in Microarray Analysis of Massively Aneuploid Genomes: Lessons from a Case of B-Lymphoblastic Leukemia. Atlas Genet Cytogenet Oncol Haematol. in press.
  • Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O'Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018 Oct;103(10):1662-1668.
  • Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MO, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, Nakamura R. Melphalan-Based Reduced Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Sep;24(9):1828-1835.
  • Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 Jun 15;124(12):2541-2551.
  • Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AA, Forman SJ, Marcucci G, Pullarkat V. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 Sep;103(9):e404-e407.
  • Mei M, Chen R. How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):26-33.
  • Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen S, Kwak L, Nademanee A, Forman S, Chen R. Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma. Ann Oncol. 2018 Mar 1;29(3):724-730.
  • Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde E, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520.
  • Mei M, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869.
  • Bentley TGK, Cohen JT, Elkin EB, Huynh J, Mukherjea A, Neville TH, Mei M, Copher R, Knoth R, Popescu I, Lee J, Zambrano JM, Broder MS. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. J Manag Care Spec Pharm. 2017 Jun;23(6-a Suppl):S34-S48.
  • Bentley TGK, Cohen JT, Elkin EB, Huynh J, Mukherjea A, Neville TH, Mei M, Copher R, Knoth R, Popescu I, Lee J, Zambrano JM, Broder MS. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. Value Health. 2017 Feb;20(2):200-205.
  • Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan;35(1):24-31.
  • Bentley TG, Cohen JT, Elkin EB, Huynh J, Mukherjea A, Neville TH, Mei M, Copher R, Knoth RL, Popescu I, Zambrano JM, Chang E, Broder MS, Lee J. A Novel Method for Evaluating Value Assessment Frameworks. Value in Health. 2016;19(7):A376.
  • Mei M, Somlo G. The role of transplant in multiple myeloma. J Natl Compr Canc Netw. 2014 Aug;12(8):1131-8.
  • Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY. Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen. Biol Blood Marrow Transplant. 2014 Dec;20(12):2072-5.
  • Mei M, Thomas S, Chen R. Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody-Drug Conjugates: Focus on Brentuximab Vedotin. BioDrugs. 2014 Jun;28(3):245-51.
  • Krishnan AY, Mei M, Sun C, Thomas SH, Teh JB, Kang T, Htut M, Somlo G, Sahebi F, Forman SJ, Bhatia S. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013 Feb;19(2):260-5.
  • Mei M, Zhu X, Harrison K, Su B, Previll L, Jackson L, Cai DX, Perry G, Zhu X. Distribution, levels, and phosphorylation of Raf-1 in Alzheimer’s disease. J Neurochem. 2006 Dec;99(5):1377-88.
  • Zhu X, Mei M, Lee HG, Wang Y, Han J, Perry G, Smith MA. P38 activation mediates amyloid-beta cytotoxicity. Neurochem Res. 2005 Jun-Jul;30(6-7): 791-6.
In The News